clinical trial · NCT07095465
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
Lewy Body Dementia PsychosisACP-204
brief summary
A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
started
Nov 14, 2025
primary completion
Feb 1, 2029
completion
Mar 1, 2029
last updated
Apr 22, 2026
official title
52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol